Hosted on MSN23h
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug
Viking Therapeutics VKTX announced that it has started the phase II VENTURE-Oral Dosing study to evaluate the safety and ...
Viking Therapeutics initiates Phase 2 VENTURE-oral dosing trial of VK2735
Viking Therapeutics (VKTX) announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual ...
3 Mid-Cap Stocks That Could Take Off in 2025
Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more ...
BioSpace3d
Higher Biopharma M&A Activity ‘Almost Inevitable’ in 2025, With Viking as Top Candidate: Analysts
Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.
Should You Buy the Dip on This High-Flying Stock?
It's been an excellent year for Viking Therapeutics ( VKTX 4.30%), a mid-cap biotech company. Thanks to impressive mid-stage ...
BioSpace1d
FDA Proposes Setting Bar for Weight-Loss Therapies as Obesity Space Heats Up
In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...
Seeking Alpha22d
Viking Therapeutics: Competition Fears Are Exaggerated
Viking Therapeutics' VK2735 reported promising results in February, with significant weight loss, however, shares have returned to prices before reporting VENTURE Phase II results. The company's ...